A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Prostate cancer often relies on androgens for growth.
• Androgen deprivation therapy (ADT) aims to reduce androgen levels.
• Persistent prostate cancer during ADT suggested alternative androgen sources.

Purpose of the Study:

• To review the concept of intracrine androgen metabolism in prostate cancer.
• To explain the persistence of prostate cancer during ADT.
• To highlight the development of targeted therapies based on this understanding.

Main Methods:

• Review of existing literature on intracrine androgen metabolism.
• Discussion of radioimmunoassay and mass spectrometry in prostate tissue.
• Analysis of the impact of understanding intracrine synthesis on drug development.

Main Results:

• Prostate cancer cells can synthesize their own testosterone (intracrine synthesis).
• This intracrine activity explains cancer persistence during ADT.
• This understanding led to FDA approval of abiraterone, an androgen metabolism inhibitor.

Conclusions:

• Intracrine androgen synthesis is a key mechanism in castration-recurrent prostate cancer.
• Targeting intracrine metabolism offers a therapeutic strategy.
• Further research may yield improved treatments with fewer side effects.